Gc. Mussa et al., Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years, J PED END M, 12(4), 1999, pp. 537-541
Seventeen pediatric patients (mean age at diagnosis 10 yr and 9 mo +/- 2 yr
and 9 mo) with Graves' disease treated with 0.3-0.7 mg/kg/day methimazole
and followed for at least three years, during which drug suspension was att
empted on attainment of good clinical and metabolic compensation, were retr
ospectively studied to look for factors predictive of lasting remission pre
sent at onset. Lasting remission was defined as a clinical and laboratory p
icture of euthyroidism lasting at least one year in the absence of treatmen
t at the end of the follow-up. A distinction was drawn between patients who
reached remission after one or two courses (groups 1 and 2) and those who
never attained a lasting remission (group 3), TRAb (TBIAb) levels at onset
were the only factor significantly correlated with the response to treatmen
t. Age at diagnosis, goiter size and fT(3) and fT(4) concentrations were no
t significantly correlated with the clinical picture. The series was too sm
all to allow any assessment of the real importance of these factors, though
a generally better response was displayed by children over 11 years old, w
ithout appreciable or with very small goiter and moderately increased thyro
id hormone levels at onset (fT(3) < 25 pg/ml in 10/10 in groups 1 and 2 and
2/7 in group 3 patients; fT(4) < 40 pg/ml in 7/10 in groups 1 and 2 and 3/
7 in group 3 patients), It was also found that better results were obtained
when the initial drug course was protracted for at least two years.